Australia · Delayed Price · Currency is AUD SomnoMed Statistics
Total Valuation
SomnoMed has a market cap or net worth of AUD 169.64 million. The enterprise value is 157.06 million.
| Market Cap | 169.64M |
| Enterprise Value | 157.06M |
Important Dates
The next estimated earnings date is Friday, August 22, 2025.
| Earnings Date | Aug 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SomnoMed has 216.11 million shares outstanding. The number of shares has increased by 108.63% in one year.
| Current Share Class | 216.11M |
| Shares Outstanding | 216.11M |
| Shares Change (YoY) | +108.63% |
| Shares Change (QoQ) | +42.66% |
| Owned by Insiders (%) | 6.96% |
| Owned by Institutions (%) | 28.57% |
| Float | 103.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 228.20 |
| PS Ratio | 1.69 |
| PB Ratio | 3.57 |
| P/TBV Ratio | 4.32 |
| P/FCF Ratio | 209.61 |
| P/OCF Ratio | 73.19 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 78.72, with an EV/FCF ratio of 194.06.
| EV / Earnings | -26.18 |
| EV / Sales | 1.57 |
| EV / EBITDA | 78.72 |
| EV / EBIT | n/a |
| EV / FCF | 194.06 |
Financial Position
The company has a current ratio of 1.81, with a Debt / Equity ratio of 0.12.
| Current Ratio | 1.81 |
| Quick Ratio | 1.52 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 2.96 |
| Debt / FCF | 7.30 |
| Interest Coverage | -3.09 |
Financial Efficiency
Return on equity (ROE) is -15.51% and return on invested capital (ROIC) is -2.92%.
| Return on Equity (ROE) | -15.51% |
| Return on Assets (ROA) | -2.14% |
| Return on Invested Capital (ROIC) | -2.92% |
| Return on Capital Employed (ROCE) | -4.58% |
| Revenue Per Employee | 334,151 |
| Profits Per Employee | -20,000 |
| Employee Count | 300 |
| Asset Turnover | 1.44 |
| Inventory Turnover | 6.94 |
Taxes
In the past 12 months, SomnoMed has paid 1.78 million in taxes.
| Income Tax | 1.78M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +115.07% in the last 52 weeks. The beta is 0.99, so SomnoMed's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | +115.07% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 0.53 |
| Relative Strength Index (RSI) | 66.53 |
| Average Volume (20 Days) | 68,279 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SomnoMed had revenue of AUD 100.25 million and -6.00 million in losses. Loss per share was -0.03.
| Revenue | 100.25M |
| Gross Profit | 60.16M |
| Operating Income | -2.38M |
| Pretax Income | -4.22M |
| Net Income | -6.00M |
| EBITDA | -544,982 |
| EBIT | -2.38M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 18.50 million in cash and 5.91 million in debt, giving a net cash position of 12.59 million or 0.06 per share.
| Cash & Cash Equivalents | 18.50M |
| Total Debt | 5.91M |
| Net Cash | 12.59M |
| Net Cash Per Share | 0.06 |
| Equity (Book Value) | 47.46M |
| Book Value Per Share | 0.22 |
| Working Capital | 18.64M |
Cash Flow
In the last 12 months, operating cash flow was 2.32 million and capital expenditures -1.51 million, giving a free cash flow of 809,324.
| Operating Cash Flow | 2.32M |
| Capital Expenditures | -1.51M |
| Free Cash Flow | 809,324 |
| FCF Per Share | 0.00 |
Margins
Gross margin is 60.01%, with operating and profit margins of -2.38% and -5.99%.
| Gross Margin | 60.01% |
| Operating Margin | -2.38% |
| Pretax Margin | -4.21% |
| Profit Margin | -5.99% |
| EBITDA Margin | -0.54% |
| EBIT Margin | -2.38% |
| FCF Margin | 0.81% |
Dividends & Yields
SomnoMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -108.63% |
| Shareholder Yield | n/a |
| Earnings Yield | -3.54% |
| FCF Yield | 0.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 27, 2009. It was a reverse split with a ratio of 0.05.
| Last Split Date | Nov 27, 2009 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
SomnoMed has an Altman Z-Score of 1.53 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.53 |
| Piotroski F-Score | 5 |